Bench-to-Bedside Translation of Cellular Immunotherapy for Pediatric Acute Myeloid Leukemia (AML) - Enduring

Acute Myeloid Leukemia (AML) is a devastating pediatric diagnosis and refractory or multiple relapsed patients have dismal outcomes.  Novel advancements in the field are occurring with CD33 CAR T-cells and FLT3 CAR T-cells, which are only available at select centers and does not currently include City of Hope. 

The advancements in these CARs is a novel therapeutic strategy for this diagnosis and, while we cannot open these specific trials at City of Hope as we do not have the viral vector to make these CAR T-cells, we can refer patients to these centers in the interim and obtain insight from their experiences, should we have the ability to open our own AML CAR T-cell trials in the future.

Target Audience

City of Hope Pediatric Hematology/Oncology Physicians, Advance Practice Practitioners, City of Hope staff and research teams.

Learning Objectives

  • Integrate management strategies into patient care (who and when to refer, how to care for afterwards).
  • Apply principles of management to pediatric CAR T-cell immunotherapy. 
  • Discuss this therapeutic option with patients.

Additional Information

AttachmentSize
PDF icon AB 1195 Bibliography159.11 KB
Activity summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
    City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
    City of Hope designates this Bench-to-Bedside Translation of Cellular Immunotherapy for Pediatric Acute Myeloid Leukemia (AML) - Enduring for a maximum of 1.00 AMA PRA Category 1 Credit™ requirements. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.00 Attendance
Activity opens: 
08/13/2021
Activity expires: 
08/13/2022
Part of: 
Pediatric Grand Rounds | Recordings
Internet
United States

This activity has been planned and implemented in strict compliance with the accreditation requirements, standards, and policies of the ACCME. City of Hope takes responsibility for the content, quality and scientific integrity of this CME activity.

As an accredited CME provider City of Hope requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 24 months, including financial relationships of a spouse that could create a conflict of interest. Any potential conflicts relative to the previous disclosure have been resolved.

Presenter: Dr. Sarah K. Tasian has indicated that she receives Grant/Research Support from Beam Therapeutics, Gilead Sciences and Incyte Corporation, and is a Consultant for Aleta Biotherapeutics and Kura Oncology.

City of Hope further encourages faculty/ authors to identify investigational products or off-label uses of products regulated by the U.S. Food and Drug Administration, at first mention and where appropriate in the content.

The information and opinions presented in this activity do not constitute medical or legal advice. Health care providers must exercise their own professional judgment in their clinical practice, and when confronted with the issues discussed herein, should not substitute this curriculum for the advice of legal counsel or application of sound ethical principles.

Bench-to-Bedside Translation of Cellular Immunotherapy for Pediatric Acute Myeloid Leukemia (AML) - Enduring has received no commercial support.

ACCREDITATION STATEMENT: City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION: City of Hope designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

The following credit type(s) are being offered for this course:

•  AMA PRA Category 1 Credit™  1.0

The following may apply AMA PRA Category 1 Credit™ for license renewal:

Registered Nurses: Nurses may report up to 1.0 credit hours toward the continuing education requirements for license renewal by their state Board of Registered Nurses (BRN). AMA PRA Category 1 Credit™ may be noted on the license renewal application in lieu of a BRN provider number.

Physician Assistants: The National Commission on Certification of Physicians Assistants states that AMA PRA Category 1 Credit™ accredited courses are acceptable for CME requirements for recertification.
 

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
    City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
    City of Hope designates this Bench-to-Bedside Translation of Cellular Immunotherapy for Pediatric Acute Myeloid Leukemia (AML) - Enduring for a maximum of 1.00 AMA PRA Category 1 Credit™ requirements. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.00 Attendance
Please login or register to take this activity.

You must be logged in to access this Enduring. 

If you are a New User, please create an account first, by clicking on "Register". 

Once Logged in: 

Click on "Start Activity" to access the educational content for this Enduring activity.

Required Hardware/software

Current version of Edge, Firefox, Safari, or Chrome.